Systimmune Inc.
Clinical trials sponsored by Systimmune Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug BL-M11D1 takes aim at tough leukemia in early trial Results expected Dec 2026 (estimated)
- New drug candidate BL-M05D1 enters early human trials for tough cancers Results expected Feb 2027 (estimated)
- New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial Results expected Sep 2027 (estimated)
-
New drug candidate BL-M05D1 enters early human trials for tough cancers
Disease control OngoingThis early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug BL-M17D1 targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC